Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects.

ABSTRACT: Advances in the genomic, molecular and immunological make-up of melanoma allowed the development of novel targeted therapy and of immunotherapy, leading to changes in the paradigm of therapeutic interventions and improvement of patients' overall survival. Nevertheless, the mechanisms regulating either the responsiveness or the resistance of melanoma patients to therapies are still mostly unknown. The development of either the combinations or of the sequential treatment of different agents has been investigated but without a strongly molecularly motivated rationale. The need for robust biomarkers to predict patients' responsiveness to defined therapies and for their stratification is still unmet. Progress in immunological assays and genomic techniques as long as improvement in designing and

SUBMITTER: Pilla L 

PROVIDER: S-EPMC7699774 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature